Purchase Order 36C26025P0576

Award Date 6/28/25
Potential Completion Date 6/27/26
Potential Value $129K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bartlett, TN 38134, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $40,697.68 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the supply of specialty pharmaceutical products, including medications to treat pulmonary arterial hypertension, neuropathic lysosomal storage disorders, and ophthalmic disorders. The contract has an ultimate completion date of March 14, 2025 and is part of the VA's Veterans...
This is a $103,003.20 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company specializing in specialty pharmaceutical services. The contract is for the delivery of various complex and high-value medications, primarily to support the VA's Veterans Integrated Service Network (VISN) healthcare facilities. Key medications provided under this contract include drugs used to treat...
This is a firm fixed-price purchase order awarded by the Veterans Integrated Service Network 19 (VISN 19) of the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the express delivery of second quarter pharmacy orders with a ceiling value of $86,938.57 and a completion date of July 24, 2017. Accredo Health Group, Inc. is a key distributor of complex and high-value medications, primarily serving the...
This is a $32,078.04 firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a specialty pharmacy services provider. The contract, which does not have a set-aside designation, is for the delivery of various high-value medications to support the VA's healthcare services for veterans, including treatments for conditions such as pulmonary arterial hypertension, neuropathic lysosomal storage disorders, and ophthalmic disorders....
This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company specializing in specialty pharmaceutical services. The contract, valued at $160,429.83, is for the delivery of the medication Uptravi 1600mcg, which is used to treat pulmonary arterial hypertension (PAH). The contract is part of the VA's efforts to provide critical medications to veterans through its Veterans...
The U.S. Department of Veterans Affairs (VA) awarded a $81,342.18 firm fixed-price purchase order contract to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, to provide the specialty pharmaceutical TYVASO. The contract, which does not have a set-aside designation, is to support the VA's Veterans Integrated Service Network 21 (VISN 21) and has an ultimate completion date of September 30, 2022. Accredo Health Group, Inc. is a key distributor of complex and...
This federal contract award, with the ID VA25917E0551, was issued by the Department of Veterans Affairs (VA) to the prime contractor Accredo Health Group, Inc., a for-profit pharmacy benefit management company specializing in specialty pharmaceutical services. The award consists of 13 firm fixed-price purchase orders totaling $108,039.41, with an ultimate completion date of September 30, 2016. The contract does not have a set-aside designation. Accredo Health Group, Inc. has been a long-standing...
This is a $81,632.25 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit subsidiary of Express Scripts that specializes in providing specialty pharmaceutical services. The contract is for the delivery of the medication Tyvaso, which is used to treat pulmonary arterial hypertension. The contract has no set-aside designation and was awarded on April 6, 2021, with a completion date of September 30, 2021....
This firm fixed-price purchase order, valued at $8,906.37, was awarded by the National Institutes of Health (NIH) Clinical Center to Accredo Health Group, Inc., a specialty pharmacy services provider. The contract is for the delivery of specific medications, such as Uptravi, Tyvaso, and Oxervate, to support treatment programs for the Veterans Health Administration (VHA). Accredo is a subsidiary of Express Scripts and has an established role as a key pharmaceutical distributor in the VA's...
This is a federal contract award to Accredo Health Group, Inc., a prime contractor, by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Veterans Integrated Service Network 5. The contract is for the "RATIFICATION OF UNAUTHORIZED COMMITMENT" and "MEDICAL PRESCRIPTION" services, with a potential value of $130,050.45. The contract is a Firm Fixed Price Purchase Order with no set-aside designation, and the period of performance runs through March 31,...

This is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs' Veterans Integrated Service Network 20 (VISN 20) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract, valued at $128,503.56, is for a bulk order of the specialty pharmaceutical Lumryz. As a prime contractor, Accredo Health Group, Inc. has a history of providing specialized medications to the VA's VISNs, with a focus on drugs treating conditions such as pulmonary arterial hypertension, neuropathic lysosomal storage disorders, and ophthalmic issues. This contract does not have a set-aside designation and is scheduled for completion by June 27, 2026.

Generated 3/27/25, 9:57 AM